Results 11 to 20 of about 30,927 (236)
Ibrutinib-induced cardiomyopathy [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2019 The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic ...
Htay Htay Kyi +2 more
openaire +4 more sources
Ibrutinib in hematoonkology [PDF]
Klinická farmakologie a farmacie, 2016 Poznani funkce B-buněcneho receptoru a jeho signalizacni kaskady umožnilo vývoj molekul, ktere inhibuji jednotlive enzymy teto drahy. Ibrutinib je inhibitor Brutonovy tyrozinkinazy, ktera ma klicove postaveni v přenosu signalu tohoto receptoru. V soucasne době je preparat registrovaný pro lecbu relabujici a refrakterni B-chronicke lymfocytarni leukemie,
Juraj Ďuraš +4 more
openaire +2 more sources
Ibrutinib for B cell malignancies [PDF]
Experimental Hematology & Oncology, 2014 Research over the role of Bruton's agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765),
Delong Liu +5 more
openaire +3 more sources
Indian Journal of Medical and Paediatric Oncology, 2020 AbstractIbrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy.
openaire +2 more sources
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]
, 2014 Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani +59 more
core +1 more source
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]
, 2018 Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with ...
Bartlett, Nancy L, et al.,
core +9 more sources
Choosing ibrutinib wisely [PDF]
Blood, 2018 In this issue of Blood , Bartlett et al share their experience with the use of ibrutinib in patients with relapsed or refractory follicular lymphoma (FL ...
openaire +3 more sources
Molecules, 2022 Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laboratory information on IBR is a prerequisite of constructing
Gellért Balázs Karvaly +5 more
openaire +3 more sources
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]
, 2015 We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén +8 more
core +2 more sources
A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]
, 2019 The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis +7 more
core +2 more sources